SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micro Computer remains under intense scrutiny after a federal indictment revealed that former employees and a co-founder allegedly used shell companies and falsified documents to smuggle controlled technology to China. While the company stated it is cooperating with authorities and was not named as a defendant, investors are heavily debating the potential for long-term reputational damage, the risk of institutional divestment, and whether the business can maintain its AI market share amidst the fallout.

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending as investors gear up for the upcoming earnings report, with heated community debate surrounding CEO compensation proposals and persistent speculation about potential large-scale acquisitions. The conversation remains heavily focused on alleged market manipulation and short-interest dynamics, keeping market participants on high alert for volatility as the earnings date approaches.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

SPDR Gold Shares (GLD) is trending due to a sharp, unexpected pullback that has traders debating whether the ETF is experiencing a liquidity-driven liquidation or a fundamental breakdown of its safe-haven status. Investors are actively discussing the impact of rising bond yields and oil price volatility on gold, with community sentiment divided between those aggressively buying the dip as a long-term hedge against national debt and others warning of further technical downside.

Lucid Group, Inc. manufactures electric vehicles. It designs, develops, and builds energy storage systems for electric vehicles and supplies automakers with the battery pack system needed to power hybrid, plug-in, and electric vehicles. The company was founded in December 2007 and is headquartered in Newark, CA.

Lucid Group Inc

Lucid Group is experiencing heightened trading activity as the market reacts to mixed earnings reports and anticipation surrounding the upcoming March 12 investor event. The community is sharply divided, with bulls pointing to the potential of a mid-size vehicle platform to drive long-term growth, while bears remain focused on persistent cash burn, dilution risks, and the company's long path toward profitability.

WeShop Holdings Ltd. engages in providing a shoppable social network. It offers shopping in fashion and accessories, health and beauty, home and DIY, food and drink, travel and holidays, tech and electronics, and other popular categories. It includes a library of shoppable product reviews from a digital online shopping mall on mobile devices. The company was founded by John Garner on September 21, 2012 and is headquartered in Jersey, the United Kingdom.

WeShop Holdings Ltd - Ordinary Shares - Class A

WeShop Holdings Limited

WeShop is drawing intense community attention due to its highly volatile price action following a direct listing, with participants actively debating its potential as a short-squeeze candidate versus concerns over its low-revenue business model. Discussions are heavily focused on the company's unique reward structure that incentivizes users with equity, leading many to monitor the stock for speculative breakout opportunities reminiscent of previous low-float market runners.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Tesla is currently facing significant selling pressure and heightened volatility as traders weigh concerns over the company's aggressive pivot toward physical AI and chip manufacturing against broader market anxiety regarding geopolitical tensions. Investors remain deeply divided, with many debating the feasibility of the newly announced chip infrastructure while expressing frustration over the stock's recent multi-month decline and the influence of leadership sentiment on its valuation.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta is currently facing significant selling pressure as investors react to reports of the company shutting down its Horizon Worlds VR platform, marking a pivot away from its costly metaverse investments toward AI-driven efficiency. While some community members view the stock's recent decline as a buying opportunity, others remain skeptical about the potential return on massive capital expenditures and the impact of rumored workforce reductions.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Markets are exhibiting significant volatility as participants weigh escalating geopolitical tensions in the Middle East against ongoing concerns about stubborn inflation and interest rate trajectories. Investors are closely monitoring potential impacts on energy supplies and global stability, with community discussion highlighting a mix of defensive hedging and debates over the durability of current market valuations.

Harvest Portfolios Group Inc - Harvest Diversified High Income Shares ETF (Class A Units)

Investors are focused on HHIS as a strategic vehicle for generating monthly cash flow through a covered call strategy on high-conviction U.S. equities. The community frequently debates the trade-off between the fund's high income potential and its sensitivity to market volatility, often highlighting it as a core component for long-term income-focused portfolios.

United States Antimony Corp. engages in the extraction, processing and sale of antimony, zeolite, silver, and gold products. It operates through the following segments: United States Antimony Operations, Mexican Antimony Operations, Precious Metals Recovery, and United States Zeolite Operations. The company was founded by John C. Lawrence in June 1968 and is headquartered in Dallas, TX.

United States Antimony Corp.

United States Antimony Corp. is trending as investors digest a strong earnings beat and substantial government contract backlogs while navigating sector-wide volatility. The community remains focused on the company's role as a critical, domestic supplier for defense and high-tech industries, fueled by the strategic necessity of independent supply chains and ongoing geopolitical supply constraints.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Enveric Biosciences Announces Registration of Five Trademarks

Enveric Biosciences (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders...

<ul class="summary-bullets"><li>The patent in question is about new chemical versions of psilocybin to treat mental health conditions such as depression, anxiety, and post-traumatic stress disorder.</li><li>Enveric identified that Gilgamesh’s petition may target claims that could be relevant to another family of patents owned by the company.</li><li>These patents are aimed at the treatment of depression and anxiety, and Enveric noted that the company has licensed them to third parties for development.</li></ul>Enveric Biosciences Inc. (ENVB) on Wednesday announced that Gilgamesh Pharmaceuticals has withdrawn a challenge against the company’s patent.Enveric stated that following the withdrawal of Gilgamesh’s challenge, there are no remaining challenges against its patent.<a href="https://stocktwits.com/symbol/ENVB">Enveric shares</a> were up more than 4% in Wednesday’s opening trade.<h2 class="st-heading-2">What Is The Patent In Question About?</h2>The patent in question is about new chemical versions of psilocybin to treat mental health conditions such as depression, anxiety, and post-traumatic stress disorder (PTSD).Gilgamesh filed a challenge against the patent in August 2025. Subsequently, AbbVie Inv. (ABBV) acquired bretisilocin from the company in a deal valued at up to $1.2 billion. Gilgamesh notified the U.S. Patent and Trademark Office (USPTO) that it had become a wholly-owned subsidiary of an entity owned by AbbVie.AbbVie filed a request with the USPTO in October to withdraw the post-grant review (PGR) petition filed by Gilgamesh.Enveric identified that Gilgamesh’s petition may target claims that could be relevant to another family of patents owned by the company. These patents are aimed at the treatment of depression and anxiety, and Enveric noted that the company has licensed them to third parties for development.Under its license terms, the company is eligible to receive aggregate upfront, development, and sales milestones potentially totaling up to $205 million, in addition to royalties on future sales.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric Biosciences</a> trended in the ‘bullish’ territory, with message volumes at ‘extremely high’ levels at the time of writing.One bullish user on Stocktwits termed the withdrawal of the petition against Enveric as “huge news.”<stembedurl>https://stocktwits.com/Luckyjs38/message/645825647</stembedurl><a href="https://stocktwits.com/symbol/ENVB">ENVB stock</a> is down 39% year-to-date and 84% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/vnda-stock-rises-after-fda-accepts-imsidolimab-gpp-treatment/cZRyPfnRIGR">Vanda Pharma Stock Rises Pre-Market After FDA Accepts Imsidolimab Filing For Rare Skin Disorder</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Enveric Biosciences Announces Withdrawal Of Petition Against Its Patent — ENVB Stock Rises

The company stated that, following the withdrawal of Gilgamesh’s challenge, there are no remaining challenges against its patent.

Equity

Enveric Biosciences Announces Withdrawal of Petition Against Its Patent

Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

Enveric Biosciences, Inc. (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological...

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Enveric Biosciences, Inc. (NASDAQ: ENVB) (Enveric or the Company), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological...

<ul class="summary-bullets"><li>Enveric stated that with the molecules covered by the patent, it may be able to target key receptors in new ways.</li><li>The company said this could enable the development of drug candidates with efficacy and safety profiles previously unattainable.</li><li>Enveric added that the expanded pipeline of molecules protected by patents allows it to license and partner with pharmaceutical firms that are investing in the treatment of neuropsychiatric conditions.</li></ul>Enveric Biosciences Inc. (SOPA) shares gained over 7% in Monday’s pre-market trade after the company announced that it has been issued a patent that covers novel molecules with likely applications for the treatment of neuropsychiatric conditions.The company said that U.S. Patent No. 12,492,179 extends the protection for its pipeline of potentially neuroplastogenic, non-hallucinogenic molecules.Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/ENVB">Enveric Biosciences</a> trended in the ‘bearish’ territory at the time of writing.<h2 class="st-heading-2">Licensing Opportunity</h2>Enveric stated that with the molecules covered by the patent, it may be able to target key receptors in new ways. The company said this could enable the development of drug candidates with efficacy and safety profiles previously unattainable.Enveric added that the expanded pipeline of molecules protected by patents allows it to license and partner with pharmaceutical firms that are investing in the treatment of neuropsychiatric conditions.<h2 class="st-heading-2">Patent Details</h2>Enveric stated that the molecules covered by this patent are based on known compounds with relevant pharmacological activity. It added that these compounds are chemically altered to improve efficacy while reducing side effects compared to existing compounds.“Enveric’s growing pipeline of patented molecules expands the available opportunities to develop next-generation treatments for neuropsychiatric conditions, leveraging our innovative research,” said Enveric CEO Joseph Tucker.Enveric is a Massachusetts-based biotechnology company focused on developing small-molecule neuroplastogenic therapeutics for the treatment of psychiatric and neurological disorders.<a href="https://stocktwits.com/symbol/ENVB">ENVB stock</a> is down 99.6% year-to-date and 99.5% over the past 12 months.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/paul-krugman-warns-2026-worse-for-small-businesses/cL75twFRExT">Paul Krugman Warns 2026 Will Be Worse For Small Businesses, A Month After Small Firms Cut 120,000 Jobs</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Is ENVB Stock Rising Today?

The company said that U.S. Patent No. 12,492,179 extends the protection for its pipeline of potentially neuroplastogenic, non-hallucinogenic molecules.

Enveric Biosciences Announces Patent Issuance

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

<ul class="summary-bullets"><li>The USPTO’s Notice of Allowance signals that the agency has determined the patent is likely to be granted.</li><li>By securing this intellectual property, Enveric gains a competitive edge in the neuropsychiatric treatment space.</li><li>Enveric’s stock surged 106% in Wednesday’s premarket.</li></ul>Enveric Biosciences (ENVB) stock is drawing investors' attention on Wednesday after the company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent application covering its EVM301 Series of molecules.<a href="https://stocktwits.com/symbol/ENVB/sentiment">Enveric’s stock</a> traded over 106% higher in Wednesday’s premarket.&nbsp;<h2 class="st-heading-2">Patent Focus and Potential</h2>The USPTO’s Notice of Allowance signals that the agency has determined the patent is likely to be granted, providing Enveric with intellectual property protection for its neuroplastogenic compounds.“We believe EB-003 holds great potential as the first known compound designed to selectively engage both 5-HT₂A and 5-HT₁B receptors to deliver fast-acting, durable antidepressant and anxiolytic effects, while being specifically designed to promote neuroplasticity and minimize hallucinogenic effects, allowing administration in outpatient setting,” said Joseph Tucker, CEO, Enveric.&nbsp;By securing this intellectual property, Enveric gains a competitive edge in the neuropsychiatric treatment space, particularly for patients with limited therapeutic options. The patent also enhances the company’s ability to pursue future research and commercialization of its EVM301 compounds.<h2 class="st-heading-2">What Are Stocktwits Users Saying?&nbsp;</h2>The stock was the second-most trending equity ticker on Stocktwits. Retail sentiment around the stock jumped to ‘extremely bullish’ from ‘bearish’ territory the previous day. Message volume improved to ‘extremely high’ from ‘high’ levels in 24 hours.&nbsp;<figure class="image"><img style="aspect-ratio:936/103;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_10_090740_png_d70c080d0b.webp" alt="ENVB’s Sentiment Meter and Message Volume as of 09:00 a.m. ET on Dec. 10, 2025 | Source: Stocktwits" width="936" height="103"><figcaption>ENVB’s Sentiment Meter and Message Volume as of 09:00 a.m. ET on Dec. 10, 2025 | Source: Stocktwits</figcaption></figure>A bullish Stocktwits user said that if the drug proves safe and effective, a potential buyout exceeding $1 billion could be possible.&nbsp;<stembedurl>https://stocktwits.com/Luckyjs38/message/638708222</stembedurl>Another user expressed optimism about the low float and fresh IP update.&nbsp;<stembedurl>https://stocktwits.com/Caicong/message/638709397</stembedurl>ENVB stock has lost over 90% of its value year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/why-did-beat-stock-rocket-72-in-pre-market-today/cLIH2RhREV2">Why Did BEAT Stock Rocket 72% In Pre-Market Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Various substances are placed on cooling blocks in the PCR laboratory of the State Office for Agriculture, Food Safety and Fisheries.

Why Did ENVB Stock More Than Double In Value Today?

The company received a Notice of Allowance from the United States Patent and Trademark Office for its patent application.

Enveric Biosciences, Inc. is a biotechnology company which engages in the development of neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company was founded on February 28, 1994 and is headquartered in Cambridge, MA.

ENVB
Enveric Biosciences Inc

Feed

News

Sentiment

Fundamentals

Info

Latest ENVB News

ENVBEnveric Biosciences Inc